Macrogenics Inc Stock Price, News & Analysis

MacroGenics (NASDAQ: MGNX) has appointed Eric Risser as its new President, Chief Executive Officer, and Board member, effective August 13, 2025. Risser, who has served as Chief Operating Officer since 2022, succeeds Scott Koenig, M.D., Ph.D., who is stepping down after 24 years as CEO.

Risser brings nearly 30 years of biotech and pharmaceutical industry experience and has been with MacroGenics since 2009. Under his leadership in corporate development, the company has generated over $1.6 billion in non-dilutive capital. The outgoing CEO, Dr. Koenig, will continue to serve as Director and advisor, leaving a legacy of three FDA-approved products.

MacroGenics has entered into a royalty purchase agreement with Sagard Healthcare Partners for ZYNYZ (retifanlimab-dlwr), receiving a $70 million upfront payment. Under the agreement, Sagard will receive royalties on global net sales of ZYNYZ until reaching $140 million (2.0x return), after which MacroGenics will resume collecting all future royalties. MacroGenics maintains its other economic interests in ZYNYZ, including potential milestone payments and commercial manufacturing support. The company's cash position stands at $154.1 million as of March 31, 2025, and with this new payment and other anticipated revenues, MacroGenics expects to extend its cash runway through the first half of 2027.

MacroGenics (MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The company's management team will deliver a presentation on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL. Interested parties can access the presentation webcast through the Investor Relations section of MacroGenics' website, specifically under the "Events & Presentations" tab. The webcast recording will remain available on the company's website for 30 days after the event.

MacroGenics (NASDAQ: MGNX) reported Q1 2025 financial results and corporate updates. The company's cash position stood at $154.1 million as of March 31, 2025. Key highlights include: First patient dosed in LINNET Phase 2 study of lorigerlimab for ovarian cancer, with clinical updates expected for LORIKEET Phase 2 study in H2 2025. Revenue increased to $13.2 million from $9.1 million YoY. Net loss improved to $41.0 million compared to $52.2 million in Q1 2024. The company is advancing its ADC pipeline with MGC026, MGC028, and MGC030. Notable partnered programs include MGD024 with Gilead, ZYNYZ with Incyte, and TZIELD with Sanofi. MacroGenics projects its cash runway into H2 2026.

MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in monoclonal antibody-based cancer therapeutics, has announced it will release its Q1 2025 financial results after market close on Tuesday, May 13, 2025. The company has stated it will not host a conference call to discuss the quarterly results or corporate progress for the period ending March 31, 2025, though it may resume quarterly conference calls in the future.

MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's management team will engage in a fireside chat on May 8, 2025, at 10:30am ET, along with one-on-one meetings.

A webcast of the presentation will be available in the Investor Relations section of MacroGenics' website and will remain accessible for 30 days after the event.

MacroGenics (NASDAQ: MGNX) has reported its 2024 financial results and corporate updates. The company completed enrollment in the 150-patient LORIKEET Phase 2 study of lorigerlimab for mCRPC and plans to initiate the LINNET Phase 2 study in ovarian cancer. MacroGenics is advancing multiple novel topoisomerase 1 inhibitor-based ADCs, including MGC026, MGC028, and MGC030.

Financial highlights include:

• Cash position of $201.7 million as of December 31, 2024
• Total revenue of $150.0 million for 2024, up from $58.7 million in 2023
• Net loss of $67.0 million for 2024
• Cash runway extended into second half of 2026

The company has discontinued internal development of vobra duo and is exploring potential partnering opportunities. Notable developments include the sale of MARGENZA rights to TerSera for $40.0 million upfront, and Incyte's filing of an sBLA for retifanlimab in SCAC with anticipated approval in H2 2025.

MacroGenics (MGNX) has scheduled its fourth quarter and full year 2024 financial results conference call for March 20, 2025, after market close. The biopharmaceutical company, which specializes in developing monoclonal antibody-based cancer therapeutics, will discuss financial performance and recent corporate developments during the call at 4:30 PM ET.

Participants can register in advance for the telephone conference, and a webcast will be available in the Investor Relations section of MacroGenics' website. The webcast recording will be archived for 30 days following the call.

MacroGenics (Nasdaq: MGNX), a biopharmaceutical company specializing in cancer treatment through monoclonal antibody-based therapeutics, has announced its participation in three major investor conferences in March 2025:

• TD Cowen 45th Annual Healthcare Conference in Boston - CEO Scott Koenig will lead a fireside chat on March 5 at 10:30am ET
• Leerink Partners 2025 Global Healthcare Conference in Miami - Fireside chat scheduled for March 11 at 11:20am ET
• Barclays 27th Global Healthcare Conference in Miami - Presentation set for March 12 at 2:00pm ET

The company will conduct one-on-one meetings at all events. Webcasts will be available on MacroGenics' website under the Investor Relations section, with 30-day replay access.